Akeso Advances HER3 ADC in Breast Cancer with Phase Ib/II Trial
Event summary
- First patient enrolled in Phase Ib/II trial (AK138D1-202) for Akeso's HER3-targeted ADC AK138D1, alone or combined with ivonescimab, in advanced breast cancer.
- Trial focuses on HR+/HER2- (65% of breast cancers) and TNBC (10-20% of cases), including diverse treatment lines and PD-L1 expression levels.
- AK138D1 designed to reduce off-target toxicities and enhance tumor penetration, with early data showing robust anti-tumor activity and low hematologic toxicity.
- Akeso positions the combination as an 'IO2.0 + ADC2.0' strategy, leveraging its leadership in bispecific antibodies and next-gen ADCs.
The big picture
Akeso's trial enrollment underscores the growing emphasis on IO-ADC combinations in oncology, particularly for breast cancer subtypes with high unmet needs. The company's proprietary platforms in bispecific antibodies and ADCs position it as a key player in the next wave of targeted cancer therapies. Success here could validate its 'ADC2.0' strategy and expand its global footprint in precision oncology.
What we're watching
- Combination Strategy
- Whether Akeso's 'IO2.0 + ADC2.0' approach can differentiate it in the competitive breast cancer treatment landscape.
- Regulatory Milestones
- The pace at which AK138D1 advances through clinical stages, given its novel design and early safety advantages.
- Pipeline Integration
- How Akeso balances development of AK138D1 alongside other next-gen ADCs like AK146D1 in its ADC2.0 push.
Related topics